Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3

Clinical Pharmacology and Therapeutics

Volumn 79, Issue 3, 2006, Pages 287-

  Lundblad, Mia Sandberg ^a   Ohlsson, Staffan ^a   Johansson, Peter ^a   Lafolie, Pierre ^a   Eliasson, Erik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 2C9; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

CARDIOVASCULAR DISEASE; DOSE RESPONSE; DRUG ACCUMULATION; DRUG EXPOSURE; DRUG METABOLISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LETTER; PRIORITY JOURNAL; STEADY STATE; UNSPECIFIED SIDE EFFECT;

EID: 33644521200     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.11.007     Document Type: Letter

References (5)

1. S.D. Solomon, J.J. McMurray, M.A. Pfeffer, J. Wittes, R. Fowler, P. Finn Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 352 2005 1071 1080
2. B. Stempak, B.L. Bukaveckas, G. Koren Cytochrome P450 2C9 genotype impact on celecoxib safety and pharmacokinetics in a pediatric patient Clin Pharmacol Ther 78 2005 309 310
3. C. Tang, M. Shou, T.H. Rushmore, Q. Mei, P. Sandhu, E. Woolf In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9 correlation with CYP2C9 genotype and in-vivo pharmacokinetics Pharmacogenetics 11 2001 223 235
4. M. Sandberg, U. Yasar, P. Stromberg, J.O. Hoog, E. Eliasson Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase Br J Clin Pharmacol 54 2002 423 429
5. J. Kirchheiner, E. Stormer, C. Meisel, N. Steinbach, I. Roots, J. Brockmoller Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites Pharmacogenetics 13 2003 473 480